FUJIFILM Holdings (4901N) Q1 2026 Earnings Report

The earnings call presented a strong performance in revenue and operating income, marking record highs for Q1 and highlighting growth in Bio CDMO and imaging segments. Despite challenges from foreign exchange losses, tariffs, and a decline in the medical systems segment, the overall outlook remains positive with an effective upward revision of the full-year forecast and continuous dividend growth.

In the Q1 earnings presentation for FY2026, FUJIFILM Holdings Corporation reported record-high revenue and operating income figures, with revenue hitting JPY749.5 billion and operating income at JPY75.3 billion. Despite a decline in net income to JPY53.8 billion due to foreign exchange losses, the company maintained a robust performance across most segments. Strong sales in the Bio CDMO business, semiconductor materials, and imaging helped offset foreign exchange impacts. Operating income grew by 35.1% YoY on a currency-neutral basis, while net income increased by 10.6% YoY, also on a currency-neutral basis. For the full year, FUJIFILM aims for new record highs in revenue, operating income, and net income, with revenue projected at JPY3.28 trillion, operating income at JPY331 billion, and net income at JPY262 billion. The company has factored in the anticipated impact of US tariffs, estimating a JPY6 billion negative impact on operating income. FUJIFILM also highlighted its commitment to sustainability with initiatives like the PFAS-free ArF immersion photoresist and a new facility for refurbished multifunction devices. The company aims to continue addressing social challenges and contributing to a sustainable society.